ARTICLE | Financial News
Aura Biosciences raises $21M series B
March 6, 2015 2:27 AM UTC
Aura Biosciences Inc. (Cambridge, Mass.) raised $21 million in a series B round led by Advent Life Sciences. New investors Chiesi Ventures, Ysios Capital and Alexandria Venture Investments also participated, as did existing investors Li-Cor Biosciences (Lincoln, Neb.) and Henri Termeer, former president and CEO of Genzyme Corp.
Aura expects to start a clinical trial by YE15 of lead candidate AU011 to treat rare ocular cancers. AU011 consists of viral nanoparticles that target tumor cells conjugated to Li-Cor's IRDye 700DX, a laser-activated cytotoxin (see BioCentury Nov. 14, 2011). ...